Published in Women's Health Weekly, July 22nd, 2004
"This prospective, parallel-group, dose-escalation study evaluated the cardiac safety of trastuzumab plus EC in women with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) and determined an epirubicin dose for further evaluation," researchers in Germany report.
"HER2-positive patients received standard-dose trastuzumab plus epirubicin (60 or 90 mg/m2)/cyclophosphamide (600 mg/m2) 3-weekly (EC60 + H, n = 26; EC90 + H,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly